{"text": "In total , 330 patients have been randomly allocated to each treatment arm .The primary endpoint is in - segment late luminal loss at 9-month follow - up angiography .", "label": "", "metadata": {}, "score": "39.75131"}
{"text": "[ Designated as safety issue : No ] .Overall response rate is defined as the proportion of participants with confirmed CR or PR .Duration of response by treatment arm [ Time Frame : Time from randomization to disease progression or death , whichever occurs first , assessed up to 3 years . ]", "label": "", "metadata": {}, "score": "40.597942"}
{"text": "[ Designated as safety issue : No ] .Overall response rate is defined as the proportion of participants with confirmed CR or PR .Duration of response by treatment arm [ Time Frame : Time from randomization to disease progression or death , whichever occurs first , assessed up to 3 years . ]", "label": "", "metadata": {}, "score": "40.597942"}
{"text": "Before angiography , 100 to 300 \u03bcg nitroglycerin is administered intracoronary .The nontapered tip of the catheter is used as the calibration standard .All lesions are assessed in at least two orthogonal views ; the projection showing the smallest diameter ( worst view ) is used for quantitative coronary angiography analysis , and views with the least foreshortening are used for measuring the length of the occlusion .", "label": "", "metadata": {}, "score": "40.696888"}
{"text": "Endpoint definitions .The primary endpoint is in - segment late luminal loss at 9 months as assessed with quantitative coronary angiography .Secondary angiographic endpoints include the following : in - stent late luminal loss , acute recoil , acute gain , net luminal gain , late loss index , minimal lumen diameter , percentage of diameter stenosis , in - stent and in - segment binary restenosis and reocclusions at 9-month angiographic follow - up .", "label": "", "metadata": {}, "score": "41.590668"}
{"text": "Overall survival is defined as time elapsed from inclusion to death .Safety : clinical and laboratory toxicities or symptomatology will be graded according to NCI - CTC criteria .", "label": "", "metadata": {}, "score": "42.937233"}
{"text": "The outcome measure assessed the percentage of participants who had achieved either a Partial or Complete Response over 6 months of treatment .Radiologic imaging was scheduled to be performed at baseline , after every third treatment cycle , and at the end of treatment or time of progression unless it was done in the previous four weeks .", "label": "", "metadata": {}, "score": "43.543552"}
{"text": "Disease progression was determined through radiology imaging measurements and by clinical or symptomatic progression during or after treatment .Progression is defined per RECIST criteria v1.0 as a measurable increase in the smallest diameter of any target lesion , progression of existing non - target lesions , or the appearance of 1 or more new lesions .", "label": "", "metadata": {}, "score": "44.288254"}
{"text": "Target lesion failure [ Time Frame : at 12 months ] [ Designated as safety issue : Yes ] .Target lesion failure defined as a composite of cardiac death , myocardial infarction ( not clearly attributed to a nontarget vessel ) , or clinically indicated target lesion revascularization by percutaneous or surgical methods at 1 years .", "label": "", "metadata": {}, "score": "45.83394"}
{"text": "Safety and tolerability of treatment [ Time Frame : throughout study , grading via CTCAE 3.0 ] .Response of tumor in presence or absence of corticosteroids [ Time Frame : Objective Response Rate & Disease Control Rate in metastatic brain melanoma lesions using IR criteria after Wk 12 .", "label": "", "metadata": {}, "score": "45.90265"}
{"text": "Progression is defined as a 20 % increase in the sum of longest diameter of target lesions ( per Response Evaluation Criteria in Solid Tumors [ RECIST ] criteria ) .", "label": "", "metadata": {}, "score": "46.10982"}
{"text": "Patient - oriented composite outcome included all - cause mortality , any MI ( including nontarget vessel territory ) , and any revascularization ( including all target and nontarget vessels , regardless of percutaneous or surgical methods ) .", "label": "", "metadata": {}, "score": "46.421318"}
{"text": "The survival rate at a specified time - point is the probability that a patient is alive at that time following randomization .The rate is calculated for each treatment group using the Kaplan - Meier product - limit method .", "label": "", "metadata": {}, "score": "46.42988"}
{"text": "Original Primary Outcome Measures ICMJE ( submitted : February 19 , 2008 ) .Tumor assessment [ Time Frame : after 12 weeks of first dose and then every 6 weeks ] .", "label": "", "metadata": {}, "score": "46.735214"}
{"text": "[ Designated as safety issue : No ] .Progression - free Survival ( PFS )[ Time Frame : PFS was measured from day 1 of treatment until time of progression ( assessed every 12 weeks ) or death , whichever came first , assessed up to 30 months . ]", "label": "", "metadata": {}, "score": "47.40198"}
{"text": "Patient is currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes .Current Primary Outcome Measures ICMJE ( submitted : April 29 , 2008 ) .", "label": "", "metadata": {}, "score": "47.73142"}
{"text": "Cardiac death [ Time Frame : at 12 months ] [ Designated as safety issue : Yes ] .Cardiac death at 12 months follow - up .", "label": "", "metadata": {}, "score": "48.16211"}
{"text": "Current Primary Outcome Measures ICMJE ( submitted : April 21 , 2014 ) .Overall survival ( OS ) time by treatment arm [ Time Frame : Time from randomization until death due to any cause , assessed up to 3 years . ]", "label": "", "metadata": {}, "score": "48.326775"}
{"text": "In the case of additional stents , only the assigned stent type is used per lesion and/or vessel .Post - stent dilatation is performed with high inflation pressures in all patients .", "label": "", "metadata": {}, "score": "48.48652"}
{"text": "Secondary clinical endpoints include major adverse cardiac events , clinically driven target vessel revascularization , target vessel failure and stent thrombosis to 5-year clinical follow - up .", "label": "", "metadata": {}, "score": "49.322136"}
{"text": "Quality of life assessment [ Time Frame : Every 4 weeks from date of first treatment until the date of death from any cause , assessed approximately up to 24 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "49.56163"}
{"text": "Angiographic definitions .The duration of the coronary occlusion is at least 4 weeks and is estimated by clinical information .The estimated length of the occlusion was measured from the proximal point of the total occlusion to the most distal point of the lesion , which was visualized with the first contrast injection after successful recanalization .", "label": "", "metadata": {}, "score": "49.95619"}
{"text": "However , if no revascularization is performed at the repeated angiography , the scheduled 9-month angiography is still required .If the angiography takes place after 6 months , the 9-month angiography is omitted .", "label": "", "metadata": {}, "score": "50.093018"}
{"text": "Time to progression ( TTP )[ Time Frame : Every 8 weeks from date of first treatment until the date of first documented progression , assessed approximately up to 24 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "50.176044"}
{"text": "Duration of response will be defined as the duration from the first documentation of objective response ( CR or PR ) to the first documented disease progression .", "label": "", "metadata": {}, "score": "50.711704"}
{"text": "Duration of response will be defined as the duration from the first documentation of objective response ( CR or PR ) to the first documented disease progression .", "label": "", "metadata": {}, "score": "50.711704"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : April 25 , 2013 ) .Durable disease control rate by treatment arm [ Time Frame : Time from randomization to disease progression or death , whichever occurs first , assessed up to 3 years . ]", "label": "", "metadata": {}, "score": "51.020134"}
{"text": "Response was defined by the Response Evaluation Criteria in Solid Tumors ( RECIST ) .A responding participant had either a Complete Response ( disappearance of all target lesions ) or Partial Response ( 30 % decrease in sum of longest diameter of target lesions ) .", "label": "", "metadata": {}, "score": "51.108788"}
{"text": "Radiologic imaging was scheduled to be performed at baseline , after every third treatment cycle , and at the end of treatment or time of progression unless it was done in the previous four weeks .", "label": "", "metadata": {}, "score": "51.347034"}
{"text": "Cineangiograms are obtained before , immediately after , and at 9 months using the same views at all times .Any coronary angiography performed within 6 months after the initial procedure is considered unscheduled .", "label": "", "metadata": {}, "score": "51.651615"}
{"text": "Current Secondary Outcome Measures ICMJE ( submitted : April 21 , 2014 ) .Durable disease control rate by treatment arm [ Time Frame : Time from randomization to disease progression or death , whichever occurs first , assessed up to 3 years . ]", "label": "", "metadata": {}, "score": "51.691433"}
{"text": "Nodules must be at least 9 mm in diameter before they can be reliably detected on chest plain films .[5 ] Work done by Geddes[6 ] indicates that the natural history of a lung malignancy is to double its volume 40 times before death ensues .", "label": "", "metadata": {}, "score": "51.9095"}
{"text": "Disease Control Rate by Modified World Health Organization ( mWHO ) Tumor Assessment Criteria [ Time Frame : From Day 1 , first dose to end of Week 12 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "51.9484"}
{"text": "Gastrointestinal or genitourinary bleeding within the prior 3 months , or major surgery within 2 months .Patients in cardiogenic shock .Patients with symptomatic heart failure that preclude coronary angiography in supine position .", "label": "", "metadata": {}, "score": "52.055954"}
{"text": "Probable stent thrombosis is defined as any unexplained death within 30 days of stent implantation or any myocardial infarction , which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause .", "label": "", "metadata": {}, "score": "52.076538"}
{"text": "Length of progression - free survival by treatment arm [ Time Frame : Time from randomization to disease progression or death , whichever occurs first , assessed up to 3 years . ]", "label": "", "metadata": {}, "score": "52.225773"}
{"text": "Length of progression - free survival by treatment arm [ Time Frame : Time from randomization to disease progression or death , whichever occurs first , assessed up to 3 years . ]", "label": "", "metadata": {}, "score": "52.225773"}
{"text": "Binary restenosis is defined as stenosis of 50 % or more at follow - up angiography ) .All QCA measurements of the target lesion will be obtained in the in - stent zone , and over entire segment including the stent and its 5 mm proximal and distal margins ( in - segment zone ) .", "label": "", "metadata": {}, "score": "52.28228"}
{"text": "An event for this endpoint was defined as a progression - free survival event occurring earlier than six months , or discontinuation of treatment earlier than six months for any other reason .", "label": "", "metadata": {}, "score": "52.31357"}
{"text": "Onset of Response by Modified World Health Organization ( mWHO ) Criteria and Immune - related Response Criteria ( irRC )[ Time Frame : From Day 1 , first dose to a maximum of 4.2 months ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "52.77616"}
{"text": "Stent thrombosis [ Time Frame : at 12 months ] [ Designated as safety issue : Yes ] .ARC definition of stent thrombosis is classified and defined as follows .", "label": "", "metadata": {}, "score": "52.94023"}
{"text": "From C1D1 to death .Progression - free survival [ Time Frame : Every 8 weeks from date of first treatment until the date of first documented progression or date of death from any cause , whichever came first , assessed approximately up to 24 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.134995"}
{"text": "Inclusion criteria : .Histologically confirmed advanced , inoperable gastric adenocarcinoma .Stage IV .Measurable ( according to RECIST criteria ) or evaluable lesion .", "label": "", "metadata": {}, "score": "53.510834"}
{"text": "Long - term follow - up .Clinical follow - up is performed at 1 , 6 and 12 months and an annual evaluation up to 5 years .", "label": "", "metadata": {}, "score": "53.69506"}
{"text": "A retrospective analysis may yield valuable diagnostic information .The absence of growth over a 2-year period is the most reliable indicator of benignity .", "label": "", "metadata": {}, "score": "53.745346"}
{"text": "within 6 months after concurrent chemoradiotherapy ( including induction chemotherapy ) delivered as part of primary treatment .Life expectancy of at least 12 weeks .", "label": "", "metadata": {}, "score": "54.40789"}
{"text": "Prior history of hypertensive crisis or hypertensive encephalopathy .Diagnosed with unstable angina per NYHA or Grade 2 or greater congestive heart failure .History of myocardial infarction within 6 months of enrollment .", "label": "", "metadata": {}, "score": "54.930603"}
{"text": "A device is considered to have failed if it did not meet the requirements of the definition for clinical device success .Clinical lesion success [ Time Frame : Baseline ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "55.019974"}
{"text": "Disease control rate at 8 weeks [ Time Frame : Eight weeks after administration of the drug ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "55.37129"}
{"text": "The primary variable , physical functioning score measured by the EORTC QLQ - C30 and QLQ - STO22 instrument , will be analyzed using a paired t - test ( change from baseline after two treatment cycles ) .", "label": "", "metadata": {}, "score": "55.61166"}
{"text": "Progression - free survival will be measured from randomization to the first documentation of disease progression or death due to any cause , whichever occurs first .", "label": "", "metadata": {}, "score": "55.656464"}
{"text": "Progression - free survival will be measured from randomization to the first documentation of disease progression or death due to any cause , whichever occurs first .", "label": "", "metadata": {}, "score": "55.656464"}
{"text": "Stent thrombosis is defined as probable if sudden unexplained death occurs within 30 days or if target vessel MI occurs without angiographic documentation , and is defined as possible if a sudden unexplained death that could not be attributed to another cause occurs after 30 days .", "label": "", "metadata": {}, "score": "55.661972"}
{"text": "Therefore , should the physician opt for radiographic surveillance following discovery of an SPN , accurate measurement is of the utmost importance .Follow - up radiographs should always be compared to the initial radiograph showing the solitary pulmonary nodule .", "label": "", "metadata": {}, "score": "55.918175"}
{"text": "This study is to evaluate disease control rate ( DCR ) at 8 weeks of BKM120 administered as therapy for patient with recurrent / metastatic head and neck squamous cell carcinoma .", "label": "", "metadata": {}, "score": "56.062054"}
{"text": "Tertiary OCT endpoints at 9-month follow - up are the following : percentage of uncovered stent struts , percentage of malapposed stent struts , tissue strut thickness , and absolute and percentage intimal hyperplasia .", "label": "", "metadata": {}, "score": "56.33052"}
{"text": "These data and work by Patz et al[30 ] suggest that FDG - PET scanning can accurately distinguish benign from malignant focal lung lesions .December 2013 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "56.535248"}
{"text": "The primary endpoint was the total pain burden ( dysmenorrhoea , deep dyspareunia and non - menstrual pain ) rated on a daily basis by the patient using standard pain scales and analgesic intake as the outcome measures .", "label": "", "metadata": {}, "score": "56.649612"}
{"text": "The first human study ( BIOFLOW - I ; Clinical Trial.gov : NCT01214148 ) in patients with de novo coronary lesions showed an excellent anti - restenotic effect on the 9-month angiography .", "label": "", "metadata": {}, "score": "56.756638"}
{"text": "[ Time Frame : at 9 months ] [ Designated as safety issue : Yes ] .Difference between the postprocedure and 9-month follow - up in - stent minimum lumen diameter .", "label": "", "metadata": {}, "score": "56.81647"}
{"text": "Additionally , optical coherence tomography is performed in the first 60 randomized patients at 9 months to assess neointima thickness , percentage of neointima coverage , and stent strut malapposition and coverage .", "label": "", "metadata": {}, "score": "56.896652"}
{"text": "Evidence on chest x - ray in the previous 3 months of old or currently active TB , or other history / evidence of active TB , even if adequately treated .", "label": "", "metadata": {}, "score": "57.169724"}
{"text": "Overall Survival ( OS ) [ Time Frame : From first dose to 24 months ] [ Designated as safety issue : No ] .OS is defined as the time from date of first dose of study drug until the date of death .", "label": "", "metadata": {}, "score": "57.21118"}
{"text": "Of those measurements the following derived parameters are calculated : acute recoil , percentage of diameter stenosis , acute gain , late luminal loss , net luminal gain , and late loss index ( late loss divided by the acute gain ) .", "label": "", "metadata": {}, "score": "57.28564"}
{"text": "Patients must not have anticipation of need for a major surgical procedure during the course of the study .There are no restrictions on core biopsies , placement of a vascular access device or other minor procedures prior to registration .", "label": "", "metadata": {}, "score": "57.36661"}
{"text": "The randomization procedure is initiated after successful wire passage of the lesion .Randomization is performed using an interactive Web - based randomization system .After entering the patient 's sex , date of birth , randomization date and confirmation of eligibility , the randomization outcome is provided to the investigator / operator on the screen .", "label": "", "metadata": {}, "score": "57.450447"}
{"text": "A partial or complete small or large bowel obstruction demonstrated radiologically within 3 months prior to study enrollment .Core biopsy or other minor surgical procedure , excluding placement of a vascular access device , within 7 days prior to study enrollment .", "label": "", "metadata": {}, "score": "57.507637"}
{"text": "This study plans to use the EORTC to stratify subjects into high or low risk groups in order to ensure balanced randomization to the different treatment groups .", "label": "", "metadata": {}, "score": "57.809464"}
{"text": "History of sarcoidosis syndrome ; .Currently receiving systemic corticosteroids or other immunosuppressive medications ; .The last dose of prior chemotherapy or radiation therapy ( with the exception of palliative radiotherapy ) was received less than 2 weeks prior to randomization ; .", "label": "", "metadata": {}, "score": "57.89213"}
{"text": "The primary analysis of OS is defined as the time from randomization until death due to any cause .Original Primary Outcome Measures ICMJE ( submitted : April 25 , 2013 ) .", "label": "", "metadata": {}, "score": "57.9132"}
{"text": "Overall safety profile verified as relevance of adverse events and laboratory abnormality in the study and grades granted based on ( USA National Cancer Center ) Common Terminology Criteria for Adverse Events such as the type , frequency and severity ( CTCAE ) , v4.0 .", "label": "", "metadata": {}, "score": "58.063038"}
{"text": "Target lesion revascularization [ Time Frame : at 12 months ] [ Designated as safety issue : Yes ] .Any target lesion revascularization ( TLR ) , defined as repeat revascularization within the stented segment including 5 mm proximal and distal border zones .", "label": "", "metadata": {}, "score": "58.14028"}
{"text": "Efficacy : time to progression , overall response rate , overall survival Time to progression is defined as time elapsed from inclusion to first documented progression or death whatever the reason .", "label": "", "metadata": {}, "score": "58.197823"}
{"text": "Use of other investigational drugs within 1 month of recruitment or within 5 half - lives of the investigational agent , whichever was longer .Any haematological or biochemical abnormalities on routine screening .", "label": "", "metadata": {}, "score": "58.320786"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : February 19 , 2008 ) .Progression free survival [ Time Frame : time between the randomization date and the date of progression or death , whichever occurs first ] .", "label": "", "metadata": {}, "score": "58.709953"}
{"text": "Disease Control Rate by Immune - related Response Criteria ( irRC )[ Time Frame : From Day 1 , first dose to end of Week 12 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.773544"}
{"text": "[ Designated as safety issue : No ] .Number of participants reporting any serious adverse events [ Time Frame : Day 1 to 90 days post dose ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "58.891617"}
{"text": "[ Designated as safety issue : No ] .Number of participants reporting any serious adverse events [ Time Frame : Day 1 to 90 days post dose ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "58.891617"}
{"text": "He / she or his / her legally authorized representative provides written informed consent prior to any study related procedure .Target lesion(s ) must be amenable for PCI .", "label": "", "metadata": {}, "score": "59.06739"}
{"text": "History of myocardial infarction or unstable angina within past 6 months .New York Heart Association ( NYHA ) congestive heart failure grade 2 or greater .", "label": "", "metadata": {}, "score": "59.173046"}
{"text": "Placebo Comparator : 2 . women with a deep endometriosis nodule of at least 1 cm in diameter ; and severe pain ( at least one severe pain score on Biberoglu Behrman scale ) .", "label": "", "metadata": {}, "score": "59.229836"}
{"text": "Reocclusion is defined as a recurrent total occlusion at the previous angioplasty site .Optical coherence tomography analysis .Optical coherence tomography ( OCT ) images are obtained in a total of 60 patients equally divided between the two stent groups during the follow - up angiogram at 9 months .", "label": "", "metadata": {}, "score": "59.628372"}
{"text": "Cardiac death is defined as any death due to immediate cardiac cause ( MI , low - output failure , fatal arrhythmia ) ; death related to the procedure , nonwitnessed death , and death of unknown cause .", "label": "", "metadata": {}, "score": "59.705257"}
{"text": "This is a Phase 2b , randomized , double - blind , parallel - group study .Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo .", "label": "", "metadata": {}, "score": "59.876175"}
{"text": "This is a Phase 2b , randomized , double - blind , parallel - group study .Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo .", "label": "", "metadata": {}, "score": "59.876175"}
{"text": "Huston and Muhm[15 ] reported that a CT nodule densitometric study ( phantom reference ) combined with conventional trispiral tomography had a 77 % accuracy in the diagnosis of solitary pulmonary nodules .", "label": "", "metadata": {}, "score": "60.11432"}
{"text": "September 2009 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Index brain lesion must have resolved consequences of prior therapy that could have confounded attribution of tumor response including edema and hemorrhage .", "label": "", "metadata": {}, "score": "60.237663"}
{"text": "Angioplasty procedure .The procedure is performed by either the radial or femoral approach with standard coronary catheterization techniques .Prior to the procedure , patients receive 5,000 to 10,000 international units heparin , followed by a bolus of 5,000 international units every additional hour of the procedure .", "label": "", "metadata": {}, "score": "60.275093"}
{"text": "The final cutoff value for malapposition is 90 \u03bcm for the hybrid sirolimus - eluting stent and 110 \u03bcm for the everolimus - eluting stent .", "label": "", "metadata": {}, "score": "60.632126"}
{"text": "Density .Siegelman et al,[10 - 12 ] Proto and Thomas,[13 ] and Zerhouni et al[14 ] have extensively investigated nodule densitometry using CT .Compared with conventional chest films , CT is 10 to 20 times more sensitive to differences in density .", "label": "", "metadata": {}, "score": "60.997063"}
{"text": "Major surgery within 4 weeks prior to study treatment start , or lack of complete recovery from the effects of major surgery .Patients who can not be regularly followed up for psychological , social , family or geographic reasons .", "label": "", "metadata": {}, "score": "61.010616"}
{"text": "[ 8 ] The ensuing fibrosis and retraction may result in an overall decrease in the volume of the mass .Webb[9 ] notes that , occasionally , as a pulmonary nodule grows , it may become less well defined , and thus , appear smaller on chest films .", "label": "", "metadata": {}, "score": "61.053696"}
{"text": "1- 90 days post dose ] [ Designated as safety issue : Yes ] .Any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment .", "label": "", "metadata": {}, "score": "61.17507"}
{"text": "1- 90 days post dose ] [ Designated as safety issue : Yes ] .Any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment .", "label": "", "metadata": {}, "score": "61.17507"}
{"text": "Both spiculation and pleural tags correlated pathologically with a desmoplastic response .Lobulation ( Figure 5 ) was predominantly associated with malignancy .This finding correlated with nodular excrescences of the tumor at its leading edge .", "label": "", "metadata": {}, "score": "61.347412"}
{"text": "Quantitative strut level analysis is performed every third frame ( 0.6 mm interval ) along the entire target segment .The algorithm automatically determines the center of the luminal surface of the strut blooming and calculates its distance to the lumen contour .", "label": "", "metadata": {}, "score": "61.37066"}
{"text": "Caution must be exercised when assessing solitary pulmonary nodules for the presence of central calcification , as , occasionally , a growing lung cancer may engulf a calcified granuloma or a scar carcinoma may arise within a preexisting calcified granuloma ( Figure 3 ) .", "label": "", "metadata": {}, "score": "61.392277"}
{"text": "The first of these techniques is based on differential nodule enhancement with IV contrast material , as measured with thin - slice CT .It relies on both qualitative and quantitative differences in the blood supply of benign vs malignant lung lesions .", "label": "", "metadata": {}, "score": "61.39759"}
{"text": "A single doubling of the volume of an SPN produces a relatively small increase in its transverse diameter .Doubling times of between 7 and 465 days are strongly suggestive of malignancy , whereas doubling times that are either shorter or longer than this suggest a benign etiology .", "label": "", "metadata": {}, "score": "61.831333"}
{"text": "Initial therapy may have included high - dose therapy , consolidation , or extended therapy .Patient should be defined as recurrent or progression of disease within 6 months of last platinum chemotherapy .", "label": "", "metadata": {}, "score": "61.833233"}
{"text": "History of carcinomatous meningitis , with prior stereotactic or highly conformal radiotherapy and/or whole brain irradiation within 14 days before the first dose of ipilimumab , and documented history of autoimmune disease .", "label": "", "metadata": {}, "score": "62.139565"}
{"text": "OS is defined as the time from the first dose of study drug until the date of death .Overall survival rate is the percentage of participants known to be alive at a timepoint .", "label": "", "metadata": {}, "score": "62.537735"}
{"text": "An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement .", "label": "", "metadata": {}, "score": "62.56034"}
{"text": "PFS is defined as the time between the date of the first dose of study therapy and the date of progression or death , whichever occurs first .", "label": "", "metadata": {}, "score": "62.593475"}
{"text": "No formal statistics are performed on clinical endpoints .Analysis of clinical endpoints is performed for descriptive purposes only on an intention - to - treat principle .", "label": "", "metadata": {}, "score": "62.808147"}
{"text": "The converse is also true .Zwirewich et al[21 ] assessed a total of 96 solitary pulmonary nodules ( 85 malignant , 11 benign ) by CT .", "label": "", "metadata": {}, "score": "62.880836"}
{"text": "The rate of in - segment binary restenosis was reduced from 41 % to 11 % in favor of SES .Clinical outcome remained significantly in favor of SES for up to 5 years , despite a higher rate of late and very late stent thrombosis ( VLST ) [ 8 , 9 ] .", "label": "", "metadata": {}, "score": "63.061417"}
{"text": "It was also seen in 5 of the 11 benign lesions .A pleural tag was defined as a linear area of high attenuation surrounded by aerated lung , originating from the edge of the mass and extending peripherally to contact the pleural surface ( Figure 4 ) .", "label": "", "metadata": {}, "score": "63.44609"}
{"text": "No prior chemotherapy for metastatic breast cancer .Any number of prior hormonal therapies are allowed ; the last dose should have been administered at least 7 days prior to the initiation of protocol therapy .", "label": "", "metadata": {}, "score": "63.647095"}
{"text": "Woodring et al[24 ] evaluated the wall thickness of cavitary SPNs and found that 94 % ( 29/31 ) of cavities with a wall thickness \u00a3 4 mm were benign .", "label": "", "metadata": {}, "score": "63.747707"}
{"text": "More frequently , lung cancers may exhibit a temporary reduction in size followed by a resumption of growth .This reduction in size suggests a resolving inflammatory process .", "label": "", "metadata": {}, "score": "63.769196"}
{"text": "Recurrent angina , a positive exercise test , abnormal dobutamine stress magnetic resonance imaging and new perfusion defects on nuclear examination are considered clinical signs of restenosis .", "label": "", "metadata": {}, "score": "64.076065"}
{"text": "The study authors are responsible for data analysis and interpretation .An independent clinical event adjudication committee will review all endpoints blinded .An independent Data and Safety Monitoring Board will review all cardiac and noncardiac adverse events unblinded , including acute kidney injury , contrast nephropathy and major bleeding .", "label": "", "metadata": {}, "score": "64.17422"}
{"text": "Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) or arterial thrombotic events .Patients may not have a history of stroke or transient ischemic attack within 6 months prior to study registration .", "label": "", "metadata": {}, "score": "64.40813"}
{"text": "Patient 's informed consent .Exclusion Criteria : .Nasopharyngeal carcinoma .More than two prior lines of chemotherapy in the palliative setting .Uncontrolled , untreated brain metastasis Patients with controlled and asymptomatic CNS metastases may participate in this trial .", "label": "", "metadata": {}, "score": "64.50723"}
{"text": "Conclusions .The PRISON II and PRISON III studies have shown favorable angiographic results for both the sirolimus - eluting stent and the Resolute zotarolimus - eluting stent for the treatment of TCOs .", "label": "", "metadata": {}, "score": "64.81148"}
{"text": "The study consists of a screening period , a treatment period , a 90-day follow - up period for safety , and a long - term survival follow - up period .", "label": "", "metadata": {}, "score": "64.90371"}
{"text": "Images are acquired with an automated pullback at a rate of 20 mm / second .Prior to the pullback , a bolus of 100 to 300 \u03bcg nitroglycerine is administered .", "label": "", "metadata": {}, "score": "65.10521"}
{"text": "History of previous or concurrent malignancy within the previous 5 years except curatively treated carcinoma in situ of the uterine cervix or basal cell carcinoma of the skin .", "label": "", "metadata": {}, "score": "65.11284"}
{"text": "Note the stereotactic radiotherapy field must not have included the brain index lesion or the lesion must have been detected and confirmed to be active and progressing after receiving whole brain irradiation .", "label": "", "metadata": {}, "score": "65.1881"}
{"text": "Target vessel revascularization [ Time Frame : at 12 months ] [ Designated as safety issue : Yes ] .Target vessel revascularization , defined as any revascularization of treated vessel .", "label": "", "metadata": {}, "score": "65.37589"}
{"text": "Anti TNFa Treatment for Deep Endometriosis Associated Pain : a Randomised Placebo Controlled Trial .Endometriosis associated pain [ Time Frame : By the clinician after 1 , 2 and 3 months ; by the patient daily for 3 months ] [ Designated as safety issue : No ] . women with a deep endometriosis nodule of at least 1 cm in diameter ; and severe pain ( at least one severe pain score on Biberoglu Behrman scale ) .", "label": "", "metadata": {}, "score": "65.40956"}
{"text": "SES : .Sirolimus - eluting stents .TCO : .Total coronary occlusion .TVR : .Target vessel revascularization .VLST : .Very late stent thrombosis .", "label": "", "metadata": {}, "score": "65.65883"}
{"text": "Best Overall Response [ Time Frame : Radiologic imaging was repeated after every 3 cycles ( about every 12 weeks ) during study treatment , up to 31 months . ]", "label": "", "metadata": {}, "score": "65.71672"}
{"text": "Shape / Margins .FIGURE 4 Pleural Tag .FIGURE 5 Lobulation .Although the interface between the SPN and the normal surrounding lung can not be used as an absolute indicator of the nature of the lesion , it can provide useful information .", "label": "", "metadata": {}, "score": "65.96971"}
{"text": "Disease not amenable to curative treatment ( surgery or radiation for curative intent ) .20 years of age or older .Progressive disease defined as follows .", "label": "", "metadata": {}, "score": "66.14843"}
{"text": "Percutaneous coronary intervention ( PCI ) of total coronary occlusion ( TCO ) was limited by high rates of restenosis in patients treated with bare metal stents or plain old balloon angioplasty [ 1 - 4 ] .", "label": "", "metadata": {}, "score": "66.702805"}
{"text": "Results are expected in 2013 .Up to now there are no data available about the safety and efficacy of these newly developed DES with bioresorbable polymers in patients with TCO .", "label": "", "metadata": {}, "score": "66.80418"}
{"text": "History of abdominal fistula , GI perforation , or intra - abdominal abscess within 6 months prior to study enrollment .Serious , non - healing wound , ulcer , or bone fracture .", "label": "", "metadata": {}, "score": "66.804184"}
{"text": "Patients must not have had a major surgical procedure , open biopsy , or significant traumatic injury within 28 days prior to study registration , and must have fully recovered from any such procedure .", "label": "", "metadata": {}, "score": "66.92715"}
{"text": "PubMed View Article .Virmani R , Guagliumi G , Farb A , Musumeci G , Grieco N , Motta T , Mihalcsik L , Tespili M , Valsecchi O , Kolodgie FD : Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus - eluting stent .", "label": "", "metadata": {}, "score": "66.98169"}
{"text": "For those who remain alive and have not progressed , PFS will be censored on the date of last evaluable tumor assessment .Participants who have not died and have no recorded postbaseline tumor assessment will be censored on the date of first dose of study therapy .", "label": "", "metadata": {}, "score": "67.03781"}
{"text": "Eur Heart J 2012 , 33 : 2569 - 2619 .PubMed View Article .Ughi GJ , Adriaenssens T , Onsea K , Kayaert P , Dubois C , Sinnaeve P , Coosemans M , Desmet W , D'hooge J : Automatic segmentation of in - vivo intra - coronary optical coherence tomography images to assess stent strut apposition and coverage .", "label": "", "metadata": {}, "score": "67.32521"}
{"text": "[ Designated as safety issue : Yes ] .The primary analysis of OS will be performed after a number of deaths have occurred among the approximately 180 participants randomized .", "label": "", "metadata": {}, "score": "67.3921"}
{"text": "The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion , which includes upstream and downstream branches and the target lesion itself .", "label": "", "metadata": {}, "score": "67.42256"}
{"text": "If neointima is absent , a value of 0 is assigned .From these values , the total percentage of uncovered struts and the total volume of neointimal area are calculated .", "label": "", "metadata": {}, "score": "67.42665"}
{"text": "Finally , the contribution of various thoracic imaging modalities to the diagnosis and staging of lung cancer are discussed briefly .[ ONCOLOGY 11(9):1387 - 1402 ] .", "label": "", "metadata": {}, "score": "67.48016"}
{"text": "Distribution was estimated using the Kaplan Meier product - limit method .Stage IV disease or stage IIIC disease ( using American Joint Committee on Cancer [", "label": "", "metadata": {}, "score": "67.56222"}
{"text": "To determine the quality of life ( EORTC QLQ - C30 and QLQ - STO22 ) in patients with gastric cancer who receive combination treatment with Taxotere and Xeloda .", "label": "", "metadata": {}, "score": "67.7366"}
{"text": "Resolute Integrity zotarolimus - eluting stent ( Medtronic Cardiovascular , CA , Minnesota , USA ) .Detailed Description : .The rate of restenosis after percutaneous coronary intervention ( PCI ) has dramatically decreased since the introduction of drug - eluting stents ( DES ) .", "label": "", "metadata": {}, "score": "68.15975"}
{"text": "Histologically and/or cytologically confirmed pleural or peritoneal malignant mesothelioma .Disease not amenable to curative surgery ; .Age 18 and over at the time of consent ; .", "label": "", "metadata": {}, "score": "68.30716"}
{"text": "Overall response rate ( ORR )[ Time Frame : Every 8 weeks from date of first treatment until date of last treatment up to 24 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "68.54173"}
{"text": "OS rate at 18 months [ Time Frame : Time from randomization until death , due to any cause , or alive at 18 months . ]", "label": "", "metadata": {}, "score": "69.01354"}
{"text": "The radiologic work - up of the solitary pulmonary nodule is pursued to facilitate the resection of potentially curable lung cancers and to minimize the resection of benign nodules .", "label": "", "metadata": {}, "score": "69.231964"}
{"text": "Active , untreated central nervous system ( CNS ) metastasis ; .History of other malignancy unless the subject has been disease - free for at least 3 years ; .", "label": "", "metadata": {}, "score": "69.357"}
{"text": "Unresectable Pleural or Peritoneal Malignant Mesothelioma .Intervention ICMJE .Drug : Tremelimumab .Tremelimumab is to be administered as an IV solution , followed by observation .", "label": "", "metadata": {}, "score": "69.63771"}
{"text": "Positive cervical cytology in the previous 6 months .Previous treatment with infliximab , any drug known to affect TNF - \u03b1 levels , e.g. pentoxifylline , thalidomide and etanercept , or any human / murine recombinant products .", "label": "", "metadata": {}, "score": "69.66447"}
{"text": "Specimen radiography performed by O'Keefe et al[17 ] demonstrated the presence of calcification in 14 % of resected primary lung tumors .Several individual case reports have described malignant pulmonary nodules with high CT numbers and central calcification .", "label": "", "metadata": {}, "score": "69.73258"}
{"text": "In detail , all patients presenting with stable coronary artery disease or acute coronary syndromes and the presence of TCOs on coronary angiography are assessed for study eligibility in eight high - volume PCI hospitals in the Netherlands and Belgium .", "label": "", "metadata": {}, "score": "69.84395"}
{"text": "Patient who have not recovered to grade 1 or better from any adverse events ( except alopecia ) related to previous antineoplastic therapy before screening procedures are initiated .", "label": "", "metadata": {}, "score": "70.21334"}
{"text": "Both .Ages .16 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects The Radiologic Appearance of Lung Cancer .", "label": "", "metadata": {}, "score": "70.24738"}
{"text": "The immunogenicity titer will be reported for samples confirmed positive for the presence of anti tremelimumab antibodies .Tremelimumab blood concentration [ Time Frame : Week 5 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "70.293976"}
{"text": "The immunogenicity titer will be reported for samples confirmed positive for the presence of anti tremelimumab antibodies .Tremelimumab blood concentration [ Time Frame : Week 5 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "70.293976"}
{"text": "PubMed View Article .Suttorp MJ , Mast EG , Plokker HWT , Kelder JC , Ernst SMPG , Bal ET : Primary coronary stenting after successful balloon angioplasty of chronic total occlusions : a single - center experience .", "label": "", "metadata": {}, "score": "70.43412"}
{"text": "Placebo is to be administered as an IV solution , followed by observation .Study Arm ( s ) .Experimental : Tremelimumab .Tremelimumab .", "label": "", "metadata": {}, "score": "70.498566"}
{"text": "Clinically significant vascular disease ( e.g. , aortic aneurysm , aortic dissection)or symptomatic peripheral vascular disease .Bleeding diathesis or coagulopathy .Presence of CNS or brain metastases .", "label": "", "metadata": {}, "score": "70.61989"}
{"text": "Abdominal masses that are not confirmed and followed by imaging techniques .Cystic lesions .Women must not be pregnant or breast feeding ; premenopausal women must have a negative serum or urine beta - human chorionic gonadotropin ( Hcg ) .", "label": "", "metadata": {}, "score": "70.76456"}
{"text": "Must have adequate hematologic and hepatic function .Exclusion Criteria : .Previously received bevacizumab .History of other invasive malignancy with the exception of nonmelanoma skin cancer .", "label": "", "metadata": {}, "score": "70.959496"}
{"text": "Despite favorable anti - restenotic efficacy , safety concerns evolved after identifying an increased rate of very late stent thrombosis ( VLST ) with drug - eluting stents ( DES ) for the treatment of TCO .", "label": "", "metadata": {}, "score": "71.09505"}
{"text": "Both central nervous system ( CNS ) ( brain lesions ) and non - CNS compartments ( lesions outside the brain ) are considered for the global BOR .", "label": "", "metadata": {}, "score": "71.17729"}
{"text": "Cavitation is seen in 2 % to 16 % of lung cancers .Occasionally , a thin - walled cavity may be associated with malignancy .", "label": "", "metadata": {}, "score": "71.31392"}
{"text": "An Open Label , Single Arm , Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum - based Therapy .", "label": "", "metadata": {}, "score": "71.52349"}
{"text": "JPSH , JGPT and MJS critically revised the manuscript for intellectual content , with final approval for submission of the principal investigator MJS .All authors read and approved the manuscript .", "label": "", "metadata": {}, "score": "71.52872"}
{"text": "Time from registration until treatment failure , defined as early termination of protocol therapy for any reason , first disease progression or death without progression .", "label": "", "metadata": {}, "score": "71.59075"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01826552 Deep endometriosis associated pain is believed to be caused by inflammation .", "label": "", "metadata": {}, "score": "71.64711"}
{"text": "Progression - free survival ( PFS ) is defined as the interval from registration until first disease progression , regardless of site , or death resulting from any cause , which ever occurred first .", "label": "", "metadata": {}, "score": "71.89516"}
{"text": "[25,26 ] .Swensen and colleagues[27 ] found a 20-Hounsfield - unit increase in 24 of 30 solitary pulmonary nodules subsequent to the IV administration of 100 mL of contrast material .", "label": "", "metadata": {}, "score": "71.93729"}
{"text": "Lesions with a wall thickness between 5 and 15 mm were almost equally divided between benign and malignant .The authors also noted that a smooth inner wall to the cavity was more commonly observed in lesions of benign etiology .", "label": "", "metadata": {}, "score": "72.239075"}
{"text": "Background .Percutaneous recanalization of total coronary occlusion ( TCO ) was historically hampered by high rates of restenosis and reocclusions .The PRISON II trial demonstrated a significant restenosis reduction in patients treated with sirolimus - eluting stents compared with bare metal stents for TCO .", "label": "", "metadata": {}, "score": "72.30888"}
{"text": "Written informed consent is obtained prior to the procedure .The study is performed in compliance with the standards of Good Clinical Practice ( ICH / E6/R1 ) and the Declaration of Helsinki ( Washington 2002 ) .", "label": "", "metadata": {}, "score": "72.534225"}
{"text": "This work suggests that assessment of CT enhancement of the solitary pulmonary nodule may be useful in gauging the likelihood of malignancy .FDG - PET- The second technique currently being evaluated to differentiate between benign and malignant SPNs is PET scanning with 2[F-18]-fluoro-2-deoxy - d - glucose ( FDG ) .", "label": "", "metadata": {}, "score": "72.60267"}
{"text": "Lesions that are considered non - measurable include the following : .Bone lesions .Leptomeningeal disease .Ascites .Pleural / pericardial effusion .Inflammatory breast disease .", "label": "", "metadata": {}, "score": "72.67069"}
{"text": "To evaluate time to progression ( TTP ) , overall response rate ( ORR ) and overall survival ( OS ) .Quality of life : to evaluate that QOL does not deteriorate from baseline .", "label": "", "metadata": {}, "score": "72.723114"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck .", "label": "", "metadata": {}, "score": "72.90408"}
{"text": "Inability to comply with study and/or follow - up procedures .Life expectancy of less than 12 weeks .Proteinuria at screening as demonstrated by either : .", "label": "", "metadata": {}, "score": "72.969604"}
{"text": "Adequate organ function .Availability of tissue samples ( archival tissue or rebiopsied tissues ) for molecular analysis ( representative paraffin block or unstained sections from tumor diagnostic specimen are mandatory ) .", "label": "", "metadata": {}, "score": "73.09453"}
{"text": "Progressed after previous receipt of 1 - 2 prior systemic treatment for advanced disease that included a first - line pemetrexed ( or anti - folate)-based regimen in combination with platinum agent ; .", "label": "", "metadata": {}, "score": "73.09516"}
{"text": "Therefore , 165 patients per treatment arm are included in this study .Sample size calculations were performed with the use of the NQUERY computer program ( Statistical Solutions , Saugus , MA , USA ) .", "label": "", "metadata": {}, "score": "73.09589"}
{"text": "All cross - sectional images ( frames ) are screened for quality assessment .A dedicated automated software system developed at the Leuven Medical Imaging Centre ( Odierna ) is used for quantitative OCT analysis [ 26 ] .", "label": "", "metadata": {}, "score": "73.18372"}
{"text": "August 2014 .Estimated Primary Completion Date .December 2013 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Inclusion Criteria : .", "label": "", "metadata": {}, "score": "73.23691"}
{"text": "A Multi - Center Phase II Study to Evaluate Tumor Response to Ipilimumab ( BMS-734016 ) Monotherapy in Subjects With Melanoma Brain Metastases .Brief Summary .", "label": "", "metadata": {}, "score": "73.341034"}
{"text": "Prior treatment with any investigational drug within the preceding 4 weeks .Concomitant chemotherapy , hormonal therapy or immunotherapy .Patient who can not take the oral drug .", "label": "", "metadata": {}, "score": "73.35074"}
{"text": "The study was not powered for VLST .However , the group treated with biolimus - eluting stents with bioresorbable polymers showed a reduction of VLST by 80 % relative risk at 4 years compared with conventional SES .", "label": "", "metadata": {}, "score": "73.54679"}
{"text": "BORR is defined as the number of patients whose global best overall response ( BOR ) was complete ( CR ) or partial response ( PR ) , divided by the total number of participants who received treatment .", "label": "", "metadata": {}, "score": "73.665405"}
{"text": "However , the lesions treated with the Endeavor ZES showed a higher rate of late luminal loss , and a trend towards an increased rate of target lesion revascularization compared with SES .", "label": "", "metadata": {}, "score": "73.72842"}
{"text": "Trial registration .Clinical Trials.gov : NCT01516723 .Patient recruitment started in February 2012 .Keywords .Chronic total occlusion Drug - eluting stent Angioplasty .", "label": "", "metadata": {}, "score": "73.82832"}
{"text": "Virmani R , Liistro F , Stankovic G , Di Mario C , Montorfano M , Farb A , Kolodgie FD , Colombo A : Mechanism of late in - stent restenosis after implantation of a paclitaxel derivate - eluting polymer stent system in humans .", "label": "", "metadata": {}, "score": "74.006546"}
{"text": "Size / Growth Rate .The growth rate of a solitary pulmonary nodule is quantitated by measuring its doubling time , ie , the time it takes to double in volume .", "label": "", "metadata": {}, "score": "74.350006"}
{"text": "Melanoma .Intervention ICMJE .Drug : Ipilimumab .10 mg / kg , administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance .", "label": "", "metadata": {}, "score": "74.43162"}
{"text": "With 131 patients per treatment arm , the study has 90 % power to reject the null hypothesis of inferiority of the hybrid sirolimus - eluting stent ( Orsiro ; Biotronik ) relative to the everolimus - eluting stent ( Xience Prime / Xpedition ; Abbott Vascular ) .", "label": "", "metadata": {}, "score": "74.510544"}
{"text": "Estimated Completion Date .February 2016 .Estimated Primary Completion Date .February 2016 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .", "label": "", "metadata": {}, "score": "74.55502"}
{"text": "A Phase 2b , Randomized , Double - blind Study Comparing Tremelimumab to Placebo in Second- or Third - line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma .", "label": "", "metadata": {}, "score": "74.671005"}
{"text": "Toxicity profile [ Time Frame : Every 4 weeks from date of first treatment until date of last treatment up to 24 months ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "75.02007"}
{"text": "Patients are preloaded with 300 mg aspirin and 300 to 600 mg clopidogrel at least 1 day before the procedure .Aspirin is continued at a once - daily dose of 80 to 100 mg lifelong and clopidogrel 75 mg once daily for at least 12 months .", "label": "", "metadata": {}, "score": "75.067215"}
{"text": "Current , recent ( within 4 weeks of the first infusion of this study ) , or planned participation in an experimental drug study other than a Genentech - sponsored bevacizumab cancer study .", "label": "", "metadata": {}, "score": "75.187126"}
{"text": "Department of Cardiology , Catharina Hospital .Department of Cardiology , Middelheim Hospital .References .H\u00f6her M , W\u00f6hrle J , Grebe OC , Kochs M , Osterhues HH , Hombach V , Buchwald AB : A randomized trial of elective stenting after balloon recanalization of chronic total occlusions .", "label": "", "metadata": {}, "score": "75.43324"}
{"text": "[ Time Frame : every 3 cycles , at the end of study and every 3 month ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "75.58818"}
{"text": "Serum or urine beta - Hcg negative in premenopausal women of child - bearing potential .Choosing to participate in a study is an important personal decision .", "label": "", "metadata": {}, "score": "75.977234"}
{"text": "The study is supported by an unrestricted grant from Biotronik SE & Co. KG .The sponsor has no role in the study design , data collection , analysis , interpretation of the data , drafting of the final manuscript , or the decision to submit the manuscript for publication .", "label": "", "metadata": {}, "score": "76.56396"}
{"text": "ECOG performance status of 0 or 1 .Recovered from any recent surgery for at least 30 days and is free of active infection .Received the following prior therapy at time of enrollment : .", "label": "", "metadata": {}, "score": "76.69226"}
{"text": "Evidence of a documented HIV infection , active hepatitis - B or C , or an opportunistic infection ( e.g. herpes zoster , cytomegalovirus , pneumocystis carinii , aspergillosis , histoplasmosis , or mycobacteria other than TB ) in the previous 6 months .", "label": "", "metadata": {}, "score": "76.77969"}
{"text": "One promising approach to the treatment of cancer is inhibition or modulating the crucial signal transduction pathway of PI3K - Akt - mTOR .Several PI3 K inhibitors are being tested in the clinical trials for cancer treatment but not for the head and neck cancer yet .", "label": "", "metadata": {}, "score": "76.83907"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Randomized , Double - blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma .", "label": "", "metadata": {}, "score": "77.13878"}
{"text": "Interventional .Study Phase .Phase 2 .Study Design ICMJE .Endpoint Classification : Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "77.17218"}
{"text": "Interventional .Study Phase .Phase 2 .Study Design ICMJE .Endpoint Classification : Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "77.17218"}
{"text": "PubMed View Article .Rationale and design of the CIBELES ( non - acute Coronary occlusion treated by EveroLimus - Eluting Stent ) trial .EuroIntervention 2010 , 6 : 112 - 116 .", "label": "", "metadata": {}, "score": "77.635124"}
{"text": "To determine the quality of life in patients with gastric cancer who receive combination treatment with docetaxel and capecitabine .Secondary endpoints are time to progression , overall response rate and overall survival .", "label": "", "metadata": {}, "score": "77.8042"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases .", "label": "", "metadata": {}, "score": "78.00073"}
{"text": "FACT - H&N questionnaire includes physical well - being ( PWB ) , social / family well - being ( SWB ) , emotional well - being ( EWB ) , functional well - being ( FWB ) , and head & neck cancer subscale ( HNCS ) .", "label": "", "metadata": {}, "score": "78.0983"}
{"text": "To address these limitations , new DES with bioresorbable polymer coatings have been developed .These polymers degrade gradually over the course of several months , resulting in controlled drug release without leaving inflammatory stimuli .", "label": "", "metadata": {}, "score": "78.142975"}
{"text": "Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone .", "label": "", "metadata": {}, "score": "78.2446"}
{"text": "Patients with a history of gastrointestinal ( GI ) perforation within 12 months prior to registration are not eligible .Patients with a history of significant bleeding episodes ( e.g. , hemoptysis , upper or lower GI bleeding ) within 6 months prior to registration are not eligible .", "label": "", "metadata": {}, "score": "78.337074"}
{"text": "Placebo .Detailed Description : .After a 1 month observation period , all women received three infusions of infliximab ( 5mg / kg ) or placebo over the course of 6 weeks .", "label": "", "metadata": {}, "score": "78.483925"}
{"text": "Original Primary Outcome Measures ICMJE .Same as current .Change History .No Changes Posted .Current Secondary Outcome Measures ICMJE ( submitted : April 29 , 2008 ) .", "label": "", "metadata": {}, "score": "78.49415"}
{"text": "A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent , Platinum - Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma .6-month Progression - Free Rate [ Time Frame : 6 months after initiation of study treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "78.52246"}
{"text": "Longer follow - up of this cohort is needed to observe the occurrence of VLST .The everolimus - eluting stents ( EES ; Xience V / Xience Prime ; Abbott Vascular , Santa Clara , CA , USA ) , also second - generation DES , showed a low rate of late luminal loss in the treatment of nonobstructive lesions with favorable clinical outcome [ 15 ] .", "label": "", "metadata": {}, "score": "78.58824"}
{"text": "The objective of the study is to assess whether the outcome of treatment with the hybrid sirolimus - eluting stent is non - inferior to the outcome of treatment with the everolimus - eluting stent in patients with TCOs .", "label": "", "metadata": {}, "score": "78.599976"}
{"text": "Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone .", "label": "", "metadata": {}, "score": "78.60991"}
{"text": "Approximately 564 subjects will be enrolled at study centers in multiple countries .The study consists of a screening period , a treatment period , and a 90-day follow - up period .", "label": "", "metadata": {}, "score": "78.67021"}
{"text": "However , the operator is informed about the assigned stent .Study oversight .The PRISON IV study is a prospective , randomized , multicenter clinical trial performed in six Dutch and two Belgian high - volume PCI hospitals .", "label": "", "metadata": {}, "score": "78.739044"}
{"text": "Over 95 % of all primary lung tumors are bronchogenic carcinomas .These are subdivided into four main cell types : squamous cell carcinoma , small - cell carcinoma , adenocarcinoma , and large - cell carcinoma .", "label": "", "metadata": {}, "score": "78.740715"}
{"text": "Median TTP and OS will be estimated using the Kaplan - Meier method .The ORR will be summarized .Safety variables will be summarized descriptively .", "label": "", "metadata": {}, "score": "78.78015"}
{"text": "Eastern Cooperative Oncology Group performance status of 0 or 1 .Required values for initial laboratory tests : .Age 16 years and older .Males and females .", "label": "", "metadata": {}, "score": "78.790405"}
{"text": "[28 ] Nonmalignant entities fail to show glucose hypermetabolism .Gupta et al[29 ] used FDG - PET imaging to evaluate 30 patients with solitary noncalcified pulmonary nodules .", "label": "", "metadata": {}, "score": "78.80579"}
{"text": "Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone .", "label": "", "metadata": {}, "score": "78.80774"}
{"text": "Suttorp MJ , Laarman GJ : A randomized comparison of sirolimus - eluting stent implantation with zotarolimus - eluting stent implantation for the treatment of total coronary occlusions : Rationale and design of the PRImary Stenting of Occluded Native coronary arteries III ( PRISON III ) study .", "label": "", "metadata": {}, "score": "79.06024"}
{"text": "A number of false - negative densitometry studies have also been reported .[ 16 ] .Calcification .FIGURE 2 Calcification .FIGURE 3 Calcification Engulfed by a Neoplasm .", "label": "", "metadata": {}, "score": "79.31959"}
{"text": "We suggest multicenter single arm phase II study to determine anti - tumor effects of BKM120 in patients with recurrent and/or metastatic SCCHN who failed to prior platinum - based chemotherapy regimens .", "label": "", "metadata": {}, "score": "79.62145"}
{"text": "Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone .", "label": "", "metadata": {}, "score": "79.86209"}
{"text": "Recruitment , enrolment and randomization .In this study , a total of 330 patients are equally randomized for the treatment of TCOs with either a hybrid sirolimus - eluting stent ( Orsiro ; Biotronik ) or an everolimus - eluting stent ( Xience Prime / Xpedition ; Abbott Vascular ) .", "label": "", "metadata": {}, "score": "79.94658"}
{"text": "Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone .", "label": "", "metadata": {}, "score": "80.0449"}
{"text": "Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone .", "label": "", "metadata": {}, "score": "80.061646"}
{"text": "Among the more common central tumors , squamous cell carcinoma is more frequently associated with bronchial obstruction , a hilar mass , and cavitation .Small - cell carcinoma is often characterized by extensive , bulky mediastinal lymphadenopathy .", "label": "", "metadata": {}, "score": "80.52585"}
{"text": "[ 2 ] .The Solitary Pulmonary Nodule .FIGURE 1 Solitary Pulmonary Nodule .The reported incidence of malignancy in a solitary pulmonary nodule varies from 3 % to 6 % in mass surveys of the general population to 30 % to 60 % of resected solitary pulmonary nodules .", "label": "", "metadata": {}, "score": "80.60595"}
{"text": "The presence of a thin layer or layers of calcium in a lamellar pattern is indicative of a granuloma , usually a histoplasmoma ( Figure 2 ) .", "label": "", "metadata": {}, "score": "80.74109"}
{"text": "Contrast Enhancement .In the 1980s , the radiologic assessment of the solitary pulmonary nodule focused primarily on CT densitometry .In the 1990s , two techniques that focus on vascularity , pathophysiologic features , and pharmacodynamics have been applied to the diagnosis of the solitary pulmonary nodule .", "label": "", "metadata": {}, "score": "81.388695"}
{"text": "All the women had a menstrual cycle occurring every 25 to 40 days .If previously treated with hormonal medication for endometriosis , at least 3 months must have elapsed and they must have had at least two menstrual cycles since stopping treatment .", "label": "", "metadata": {}, "score": "81.54158"}
{"text": "However , new DES with a bioresorbable polymer coating have emerged .At the moment , none of these stents with bioresorbable polymers have been evaluated in complex lesions such as TCO .", "label": "", "metadata": {}, "score": "81.721954"}
{"text": "PubMed View Article .: ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST - segment elevation .Eur Heart J 2011 , 32 : 2999 - 3054 .", "label": "", "metadata": {}, "score": "82.04282"}
{"text": "Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone .", "label": "", "metadata": {}, "score": "82.10041"}
{"text": "Unresolved bowel obstruction or subobstruction .Chronic diarrhea .Clinically significant malabsorption syndrome .Inability to swallow tablets .Known dihydropyrimidine dehydrogenase ( DPD ) deficiency .", "label": "", "metadata": {}, "score": "82.1471"}
{"text": "PubMed View Article .JAMA 2008 , 299 : 1903 - 1913 .PubMed View Article .W\u00f6hrle J , Rottbauer W , Imhof A : Everolimus - eluting stents for treatment of chronic total coronary occlusions .", "label": "", "metadata": {}, "score": "82.34804"}
{"text": "BMS-734016 .MDX-010 .Drug : Corticosteroid : Betamethasone .Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone .", "label": "", "metadata": {}, "score": "82.37348"}
{"text": "Although Orsiro SES showed excellent results in terms of late lumen loss at 9 months in first - in - man single arm trial ( BIOFLOW - I trial ) , randomized controlled trials evaluating its efficacy and safety are limited to date .", "label": "", "metadata": {}, "score": "82.42897"}
{"text": "Those with true anaphylaxis to prior contrast media , however , should not be enrolled . )Patients who can not maintain aspirin , plavix from the study enrollment to study completion ( during 1 year ) .", "label": "", "metadata": {}, "score": "82.51744"}
{"text": "Placebo Comparator : Placebo .Placebo .Intervention : Drug : Placebo .Not Provided .Recruitment Information .Recruitment Status ICMJE .Active , not recruiting .", "label": "", "metadata": {}, "score": "82.62979"}
{"text": "The null hypothesis of inferiority of the hybrid sirolimus - eluting stent ( Orsiro ; Biotronik ) is rejected when the upper limit of the 95 % confidence interval for the observed difference in late loss falls below 0.2 mm .", "label": "", "metadata": {}, "score": "82.69776"}
{"text": "Participants in the corticosteroid - dependent arm for whom adequate control of metastatic brain lesion - related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone .", "label": "", "metadata": {}, "score": "83.17898"}
{"text": "Follow BioMed Central .Trials main menu .A randomized multicenter comparison of hybrid sirolimus - eluting stents with bioresorbable polymer versus everolimus - eluting stents with durable polymer in total coronary occlusion : rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study .", "label": "", "metadata": {}, "score": "83.735"}
{"text": "Detailed Description .GAST - TaxXel is an open , phase II , single arm , non - randomized , Finnish multicenter trial .At least 50 subjects will be enrolled .", "label": "", "metadata": {}, "score": "83.97702"}
{"text": "A solitary pulmonary nodule ( SPN ) is the most common radiographic presentation of lung cancer .The imaging characteristics of solitary pulmonary nodules are described and illustrated .", "label": "", "metadata": {}, "score": "84.27371"}
{"text": "The authors thank JP Kelder for confirmation of statistical analysis and G Kranen who made substantial contributions to data acquisition and collection .Competing interests .", "label": "", "metadata": {}, "score": "84.37745"}
{"text": "Able to comply with the scheduled follow - up and with the management of toxicities .Exclusion Criteria : .Pregnant or lactating women ( or potentially fertile women not using adequate contraception ) .", "label": "", "metadata": {}, "score": "84.65841"}
{"text": "This reflects a change in the biology of lung cancer .[ 1 ] .Although none of the four main cell types is exclusively central or peripheral in location , the majority of small - cell lung cancers and squamous cell carcinomas are centrally located .", "label": "", "metadata": {}, "score": "85.10936"}
{"text": "Both .Ages .18 Years to 99 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "85.31561"}
{"text": "Official Title ICMJE .Biweekly Docetaxel ( Taxotere \u00ae )in Combination With Capecitabine ( Xeloda \u00ae )as First - Line Treatment in Patients With Advanced Gastric Cancer .", "label": "", "metadata": {}, "score": "85.7582"}
{"text": "Same as current .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .", "label": "", "metadata": {}, "score": "85.84071"}
{"text": "TIMI Study Group :The thrombolysis and myocardial infarction ( TIMI ) trial : phase I findings .N Engl J Med 1988 , 70 ( 318 ) : 265 - 270 .", "label": "", "metadata": {}, "score": "86.28104"}
{"text": "In the PRISON III trial we compared two zotarolimus - eluting stents ( ZES ) , the Endeavor ZES and the Resolute ZES ( both Medtronic Inc. , Minneapolis , MN , USA ) , with SES in patients treated for TCO [ 14 ] .", "label": "", "metadata": {}, "score": "86.4106"}
{"text": "Official Title : .Multicenter , Randomized , Open Label , Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent .", "label": "", "metadata": {}, "score": "86.89932"}
{"text": "Taxotere .Xeloda .Study Arm ( s ) .Not Provided .Not Provided .Estimated Primary Completion Date .March 2009 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "87.06993"}
{"text": "Zotarolimus - eluting stents .Declarations .Acknowledgements .The PRISON IV trial is supported by an unrestricted grant from Biotronik SE & Co. KG .", "label": "", "metadata": {}, "score": "87.145996"}
{"text": "Official Title : .A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab - paclitaxel or Ixabepilone With or Without Bevacizumab as First - Line Therapy for Locally Recurrent or Metastatic Breast Cancer .", "label": "", "metadata": {}, "score": "87.38747"}
{"text": "Allocation : Non - Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "87.470245"}
{"text": "The patients ( aged 18 - 50 years ) were all recruited from a single , tertiary referral hospital at Leuven University , Belgium , specialising in the surgical treatment of severe endometriosis .", "label": "", "metadata": {}, "score": "87.826584"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00604864 .Endometriosis Genital Diseases , Female Antibodies , Monoclonal Infliximab Analgesics Analgesics , Non - Narcotic Anti - Inflammatory Agents Anti - Inflammatory Agents , Non - Steroidal Antirheumatic Agents .", "label": "", "metadata": {}, "score": "87.887955"}
{"text": "PubMed View Article .Am Heart J 2004 , 147 : e16-e20 .View Article .J Am Coll Cardiol 1996 , 28 : 1444 - 1451 .", "label": "", "metadata": {}, "score": "88.690186"}
{"text": "New DES with bioresorbable polymer coatings were developed to address these safety concerns .No randomized trials have evaluated the efficacy and safety of the new - generation DES with bioresorbable polymers in patients treated for TCO .", "label": "", "metadata": {}, "score": "88.783356"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Non - Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "89.44878"}
{"text": "Despite the promising results of second - generation DES , new concerns have been raised after identifying hypersensitivity reactions caused by the durable polymer coatings of DES [ 18 , 19 ] .", "label": "", "metadata": {}, "score": "89.6601"}
{"text": "Authors ' contributions .MJS , RJVdS , JJK and PHMJV were involved in the conception and design of the study .KT , TA , BJLVdB and MARB contributed to the drafting and writing of the manuscript .", "label": "", "metadata": {}, "score": "89.71428"}
{"text": "WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , or bilateral oophorectomy ) or is not postmenopausal .", "label": "", "metadata": {}, "score": "89.89256"}
{"text": "It has therefore been suggested that infliximab , an anti - TNF - \u03b1 monoclonal antibody , might relieve pain in affected women .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "90.1698"}
{"text": "The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer .", "label": "", "metadata": {}, "score": "90.53282"}
{"text": "Female of childbearing potential , unless a recent pregnancy test is negative , who possibly plan to become pregnant any time after enrollment into this study .", "label": "", "metadata": {}, "score": "90.79834"}
{"text": "History of allergy to drugs containing the excipient TWEEN 80 \u00ae and/ or 5- fluorouracil .Lack of physical integrity of the upper gastrointestinal tract .", "label": "", "metadata": {}, "score": "90.96875"}
{"text": "Stomach Neoplasms .Intervention ICMJE .Drug : docetaxel and capecitabine .biweekly docetaxel iv ( 50 mg / m2 ) on day 1 and 15 and capecitabine po 1250 mg / m2 x 2/day days 1 - 7 and 15 - 21 , treatment cycle consisting of 21 days .", "label": "", "metadata": {}, "score": "91.24083"}
{"text": "Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "91.48847"}
{"text": "Intervention : Drug : Ipilimumab .Experimental : Ipilimumab , 10 mg / kg , IV in corticosteroid - dependent patients .Participants who were dependent on corticosteroid therapy received ipilimumab , 10 mg / kg , as a 90-minute intravenous ( IV ) infusion every 3 weeks ( Weeks 1 , 4 , 7 , and 10 ) during the Induction Phase .", "label": "", "metadata": {}, "score": "92.41794"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00407563 .Neoplasms , Glandular and Epithelial Ovarian Neoplasms Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Genital Diseases , Female Genital Neoplasms , Female Gonadal Disorders Neoplasms Neoplasms by Histologic Type Neoplasms by Site Ovarian Diseases Urogenital Neoplasms Bevacizumab .", "label": "", "metadata": {}, "score": "93.82516"}
{"text": "It has a unique hybrid combination of polymers coated on thin cobalt - chromium struts ( 60um ) .The BIOlute \u00ae active component is a bioabsorbable polymer matrix combined with an anti - proliferative drug , sirolimus , and elutes the drug in a controlled manner after implantation , degrades over time and leaves only the PROBIO \u00ae coated stent behind in the long - term .", "label": "", "metadata": {}, "score": "93.87578"}
{"text": "If vomiting occurs no attempt should be made to replace the dose .Regular orange juice is allowed .Other Names : . NVP - BKM120 . BKM-120 .", "label": "", "metadata": {}, "score": "93.95052"}
{"text": "These benign lesions arise from small rests of tissue not normally found in the lung .The presence of cartilaginous elements gives rise to the popcorn calcification .", "label": "", "metadata": {}, "score": "95.09213"}
{"text": "Treatment with bisphosphonates is allowed and recommended as per American Society of Clinical Oncology ( ASCO ) guidelines .Prior trastuzumab or lapatinib required for patients with HER2 overexpressing tumors .", "label": "", "metadata": {}, "score": "95.24008"}
{"text": "N Engl J Med 2003 , 349 : 1315 - 1323 .PubMed View Article .N Engl J Med 2002 , 346 : 1773 - 1780 .", "label": "", "metadata": {}, "score": "95.4145"}
{"text": "Chimeric A2 ( infliximab , RemicadeTM ) IgG ; 100 mg infliximab IgG , Infliximab was freshly prepared immediately before each administration .Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0 , 2 and 6 .", "label": "", "metadata": {}, "score": "95.61594"}
{"text": "Note that diverticulosis is permitted ; .Active or history of inflammatory bowel disease ( eg , colitis , Crohn 's ) , irritable bowel disease , celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea .", "label": "", "metadata": {}, "score": "95.931366"}
{"text": "JACC Cardiovasc Interv 2009 , 2 : 977 - 985 .PubMed View Article .N Engl J Med 2007 , 356 : 1009 - 1019 .", "label": "", "metadata": {}, "score": "96.540726"}
{"text": "To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .For general information , see Learn About Clinical Studies .", "label": "", "metadata": {}, "score": "96.786446"}
{"text": "Experimental : BKM120 .Intervention : Drug : BKM120 .Not Provided .Recruitment Information .Recruitment Status ICMJE .Recruiting .Estimated Enrollment ICMJE .", "label": "", "metadata": {}, "score": "96.7935"}
{"text": "Head Neck Cancer Squamous Cell Metastatic .Head Neck Cancer Squamous Cell Recurrent .Intervention ICMJE .Drug : BKM120 .Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily , in a fasting state or with a light fat - free meal , and as close as possible to the same time each day .", "label": "", "metadata": {}, "score": "97.191986"}
{"text": "Department of Cardiology , St. Antonius Hospital , Koekoekslaanl .Department of Cardiology , University Hospitals Leuven .Department of Cardiology , Amphia Hospital .Department of Cardiology , Academic Medical Center , University of Amsterdam .", "label": "", "metadata": {}, "score": "97.729996"}
{"text": "The Patient group who are treated with Osiro Hybrid Drug - Eluting Stent ( Biotronik AG , Bulach , Switzeland ) .Device : Osiro Hybrid Drug - Eluting Stent .", "label": "", "metadata": {}, "score": "98.85812"}
{"text": "Experimental : Ipilimumab , 10 mg / kg , IV in corticosteroid - free patients .Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg / kg , as a 90-minute intravenous ( IV ) infusion every 3 weeks ( Weeks 1 , 4 , 7 , and 10 ) during the Induction Phase .", "label": "", "metadata": {}, "score": "99.082016"}
{"text": "Circulation 2006 , 114 : 921 - 928 .PubMed View Article .Am Heart J 2009 , 157 : 149 - 155 .PubMed View Article .", "label": "", "metadata": {}, "score": "99.150085"}
{"text": "Bevacizumab may block tumor growth by targeting certain cells and slowing the growth of blood vessels to the tumor .It is not yet known which treatment regimen is more effective in treating patients with breast cancer .", "label": "", "metadata": {}, "score": "99.73457"}
{"text": "345 Korean patients with a wide variety of coronary heart disease will be enrolled to this \" all - comers \" trial to give definite answer to the above hypothesis that is urgently needed .", "label": "", "metadata": {}, "score": "100.238144"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "101.20209"}
{"text": "Furthermore , there arises a concern about thrombogenic risk of these DES at the expense of reduced restenosis .Therefore , works aiming to reduce both restenosis and thrombosis are on - going , and there has been a rush of various second - generation DES with \" biocompatible but non - absorbable polymer \" and third - generation DES with \" bioabsorbable polymer \" .", "label": "", "metadata": {}, "score": "101.43794"}
{"text": "Exclusion Criteria : .Received any prior monoclonal antibody against CTLA-4 , programmed cell death 1 ( PD1 ) or programmed cell death 1 ligand 1 ( PD - L1 ) ; .", "label": "", "metadata": {}, "score": "102.40784"}
{"text": "United States , Australia , Belgium , Canada , Denmark , France , Germany , Hungary , Israel , Italy , Korea , Republic of , Netherlands , Poland , Romania , Russian Federation , South Africa , Spain , Sweden , United Kingdom September 2009 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "102.99167"}
{"text": "The study was approved by the Institutional Review Board of Leuven University .Written , informed consent was obtained before any study related procedures were performed .", "label": "", "metadata": {}, "score": "103.33881"}
{"text": "PubMed View Article .EuroIntervention 2006 , 2 : 286 - 294 .PubMed .J Am Coll Cardiol 2006 , 48 : 2440 - 2447 .", "label": "", "metadata": {}, "score": "104.166435"}
{"text": "Breast Neoplasms Breast Neoplasms , Male Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms , Glandular and Epithelial Carcinoma Breast Diseases Skin Diseases Bevacizumab Paclitaxel Angiogenesis Inhibitors .", "label": "", "metadata": {}, "score": "104.903114"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "105.283775"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "105.283775"}
{"text": "PubMed View Article .Circulation 2009 , 120 : 391 - 399 .PubMed View Article .Lancet 2011 , 378 : 1940 - 1948 .", "label": "", "metadata": {}, "score": "109.29713"}
{"text": "Drug : Paclitaxel Drug : Paclitaxel Albumin - Stabilized Nanoparticle Formulation Drug : Ixabepilone Biological : Bevacizumab Other : Questionnaire Administration Other : Laboratory Biomarker Analysis .", "label": "", "metadata": {}, "score": "114.16502"}
{"text": "PubMed View Article .Copyright .\u00a9 Teeuwen et al . ; licensee BioMed Central Ltd. 2012 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "128.75266"}
